MachFBaigentCCatapanoAL, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J2019, pp. 1–78.
2.
GrundySMStoneNJBaileyAL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA Guideline on the management of blood cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2019; 73: e285–e350.
3.
ReinerZDe BackerGFrasZ, et al.Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries. Findings from the EUROASPIRE IV survey. Atherosclerosis2016; 246: 243–250.
4.
FerrieresJDe FerrariGMHermansMP, et al.Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: results from DYSIS II Europe. Eur J Prev Cardiol2018; 25: 1966–1976.
5.
MunkhaugenJSverreEOtterstadJE, et al.Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol2017; 24: 981–989.
6.
HopewellJCParishSOfferA, et al.Impact of common genetic variation on response to simvastatin therapy among 18705 participants in the Heart Protection Study. Eur Heart J2013; 34: 982–992.
7.
PostmusITrompetSDeshmukhHA, et al.Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun2014; 5: 5068.
8.
LawMRWaldNJRudnickaAR, et al.Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ2003; 326: 1423–1427.
9.
De BacquerDDe SmedtDReinerŽ, et al.Percentual LDL-C response to a given statin dose is not fixed across the pre-treatment range: real world evidence from clinical practice. Eur J Prev Cardiol.2020; 27: 1630–1636.
10.
KarlsonBWWiklundOPalmerMK, et al.Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J – Cardiovasc Pharmacother2016; 2: 212–217.
11.
RidkerPMMoraSRoseL. on behalf of the JUPITER Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J2016; 37: 1373–1379.
12.
CuchelMBruckertEGinsbergHN, et al.Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J2014; 35: 2146–2157.
